- Organic sales increased by 1% while revenue fell 5% due to adverse currency effects.
- Adjusted EBITDA reached €385 million, with a €26 million negative currency impact.
- The India divestment is set to close in December 2025, with all regulatory approvals granted.
- A €300 million provision was recognized for an Australian project, with insurance coverage up to €500 million.
Q3 2025 Financial Performance
AkzoNobel reported a 1% increase in organic sales for Q3 2025, driven by price and mix improvements, despite a 5% revenue decline due to adverse currency effects. Adjusted EBITDA was €385 million, including a €26 million negative impact from currency fluctuations, compared to €394 million in Q3 2024. The adjusted EBITDA margin expanded to 15.1%, up from 14.8% in the previous year, attributed to efficiency actions.
Cash Flow and Divestment
Net cash from operating activities was positive at €331 million, an increase from €294 million in Q3 2024. The divestment of Akzo Nobel India Ltd. is on track to close in December 2025, with all necessary regulatory approvals obtained.
Outlook and Strategic Goals
AkzoNobel expects to achieve an adjusted EBITDA of approximately €1.48 billion for the full year 2025, subject to market conditions and exchange rates. The company aims to expand its profitability in the mid-term, targeting an adjusted EBITDA margin above 16% and a return on investment between 16% and 19%, supported by organic growth and industrial excellence.
Provision for Australian Project
A provision of €300 million was recognized for an Australian project from 2013-15, with €275 million affecting operating income. The provision relates to claims meeting IAS37 recognition criteria as of September 30, 2025. AkzoNobel is insured for cash outflows up to €500 million. The timing of the Federal Court of Australia's judgment is uncertain, with a decision not expected before mid-2026.
